- Corporate
Toctino
Alitretinoin belongs to the well studied family of retinoids and is targeted at
patients with severe chronic hand eczema (CHE) who do not respond to topical
corticosteroids.
Current status
Toctino® (alitretinoin) is marketed in Denmark,
France, Germany, Switzerland
and the United Kingdom. The drug is
approved in 16 additional European countries as well as in Canada and has
been recommended for approval in six further European countries.
Basilea has entered into a distribution
agreement with Almirall, S.A. for Toctino® in selected European markets
and Mexico.
Furthermore, a
phase III clinical trial on alitretinoin for the treatment of severe chronic
hand eczema is ongoing in the U.S.
© 2010 Basilea Pharmaceutica Ltd.
